Medical Device

IDE Group has announced OptoSleep as the Grand Prize Winner of the 2025 Building Better Futures for Health (BBFH) Challenge final event held during the MTAA MedTech Conference in Sydney

IDE Group has announced the finalists for the 2025 Building Better Futures for Health (BBFH) Challenge, a national initiative designed to accelerate the commercialisation of early-stage medical technologies and strengthen the foundations of Australia’s MedTech innovation ecosystem

IDE Group has launched the 2025 Building Better Futures for Health (BBFH) Challenge, a national program designed to accelerate the development of early-stage medical technologies. Delivered in collaboration with the Medical Technology Association of Australia (MTAA) MedTech Compass membership initiative

IDE Group has announced that its purpose-built ophthalmic auto-injector, OKO™, has received AU$1,200,000 grant through the Targeted Translation Research Accelerator (TTRA) program for Diabetes and Cardiovascular Disease to advance the commercialisation of OKO™.

Implementing Human-Centered Design (HCD) in MedTech start-ups presents challenges. We explore three main obstacles in integrating HCD into product development and suggest strategies for improvement.

IDE Group has been at the forefront of medical innovation for over two decades, partnering closely with leading healthcare companies and emerging disruptors to bring groundbreaking products and businesses into the market.

IDE Group announces OKO, the first auto-injector designed for ophthalmology, offering 59x greater dosing accuracy, 45% faster procedures, and 78% cost savings. Transforming retinal disease treatment.

We examine the current state of funding in women’s health, highlights key challenges, explores successful models, and outlines actionable recommendations for driving substantial change in the FemTech ecosystem.

The IDE Usability Lab uniquely merges advanced usability testing facilities with deep user-centered design expertise, empowering MedTech companies to reduce development risk, validate clinical workflows, and achieve faster, more confident market entry.

Daan Hittema discusses how IDE Group is sharpening its strategic focus, emphasising specialised areas like women’s health, helping shape the future of healthcare innovation.